Biosimilars: A cure to the U.S. health care cost conundrum?

Blood Reviews

Volumn 28, Issue 6, 2014, Pages 263-268

  Hirsch, Bradford R ^a,b   Lyman, Gary H ^c,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Biosimilar; Follow on biologic; Health care cost; Specialty pharmaceuticals

Indexed keywords

BIOSIMILAR AGENT;

CLINICAL DECISION MAKING; DISEASE MARKER; DRUG APPROVAL; DRUG LEGISLATION; DRUG MARKETING; DRUG NOMENCLATURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE COST; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; UNITED STATES; ECONOMICS;

BIOSIMILAR PHARMACEUTICALS; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 84923834669     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.08.003     Document Type: Article

References (38)

1. Kitamura M. A quarter of doctors in Europe can't define a biosimilar March 18 2014, Bloomberg, [Available at http://www.bloomberg.com/news/2014-03-18/a-quarter-of-doctors-in-europe-can-t-define-biosimilars.html].
2. Federal Trade Commission Emerging health care issues: follow-on biologic drug competition: a federal trade commission report Available at, [Accessed on May 1st, 2014]. http://www.ftc.gov/reports/emerging-health-care-issues-follow-biologic-drug-competition-federal-trade-commission-report.
3. Morgan S., Grootendorst P., Lexchin J., Cunningham C., Greyson D. The cost of drug development: a systematic review. Health Policy 2011, 100(1):4-17.
4. Center for Medicare and Medicaid Services National health expenditure projections 2012-2022 Available at, [Accessed on June 9th, 2014]. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/proj2012.pdf.
5. IMS Health The global use of medicines: outlook through 2016 Available at:, [Accessed on May 1st, 2014]. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf.
6. Hirsch B.R., Lyman G.H. Will biosimilars gain momentum?. J Natl Compr Canc Netw 2013, 11(10):1291-1297.
7. Grabowski H.G., Guha R., Salgado M. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff (Millwood) 2014, 33(6):1048-1057.
8. Patient Protection and Affordable Care Act of 2009, Pub. L. No. 111-148, Title VII, Subtitle A "Biologics Price Competition and Innovation Act of 2009", §7001-7003.
9. Center for Drug Evalation and Research Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product Available at, [Accessed on April 30, 2014]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
10. Center for Drug Evalation and Research Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference protein product Available at:, [Accessed on April 30, 2014]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
11. Center for Drug Evalation and Research Guidance for industry: formal meetings between FDA and biosimilar biological product sponsors or applicants Available at:, [Accessed on April 30, 2014]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM345649.pdf.
12. Kozlowski S., Woodcock J., Midthun K., Sherman R.B. Developing the nation's biosimilars program. N Engl J Med 2011, 365(5):385-388.
13. European Medicines Agency Guidance on similar biological medicinal products Available at:, [Accessed on April 22, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.
14. European Medicines Agency Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (revision) Available at:, [Accessed on April 22, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf.
15. European Medicines Agency Guidance on similar medicinal products containing recombinant erythropoietins Available at:, [Accessed on April 23, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf.
16. European Medicines Agency European public assessment reports for filgrastim Available at, [Accessed on April 30, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000918/WC500022469.pdf.
17. European Medicines Agency Guideline on similar biological medicinal products containing recombinant granulocyte-stimulating factor Available at:, [Accessed on April 23, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf.
18. European Medicines Agency Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - guidance on similar medicinal products containing somatropin Available at:, [Accessed on April 23, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003956.pdf.
19. Pharmaceutical Care Management Association Introduction to state biosimilar substitution laws. Presented at FTC Follow-on Biologics Workshop Available at, [Accessed on June 9th, 2014]. http://www.ftc.gov/system/files/documents/public_events/Follow-On%20Biologics%20Workshop%3A%20Impact%20of%20Recent%20Legislative%20and%20Regulatory%20Naming%20Proposals%20on%20Competition/mazer.pdf.
20. Federal Trade Commision Transcript: follow on biologics workshop Available at, [Accessed on June 9th, 2014]. http://www.ftc.gov/system/files/documents/public_events/171301/140204biologicstranscript.pdf.
21. Abbvie Reference biologic perspective on naming. Presented at FTC Follow-on Biologics Workshop Available at, [Accessed on June 9th, 2014]. http://www.ftc.gov/system/files/documents/public_events/Follow-On%20Biologics%20Workshop%3A%20Impact%20of%20Recent%20Legislative%20and%20Regulatory%20Naming%20Proposals%20on%20Competition/alexander.pdf.
22. Senior M. Biosimilars battle rages on, Amgen fights both sides. Nat Biotechnol 2013, 31(4):269-270.
23. Defrancesco L. Three deaths sink Affymax. Nat Biotechnol 2013, 31(4):270.
24. Platt R., Carnahan RM, Brown J.S., Chrischilles E., Curtis L.H., Hennessy S., et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012, 21(Suppl. 1):1-8.
25. Behrman R.E., Benner J.S., Brown J.S., McClellan M., Woodcock J., Platt R. Developing the sentinel system-a national resource for evidence development. N Engl J Med 2011, 364(6):498-499.
26. American Society of Clinical Oncology CancerLinQ - building a transformation in cancer care Available at, [Accessed on June 15th, 2014]. http://www.asco.org/cancerlinq.
27. Grabowski H., Guha R., Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov 2014, 13(2):99-100.
28. Lubenau H., Bias P., Maly A.K., Siegler K.E., Mehltretter K. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009, 47(4):275-282.
29. Lubenau H., Bias P., Maly A.K., Siegler K.E., Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009, 23(1):43-51.
30. Engert A., Griskevicius L., Zyuzgin Y., Lubenau H., del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009, 50(3):374-379.
31. del Giglio A., Eniu A., Ganea-Motan D., Topuzov E., Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008, 8:332.
32. Gatzemeier U., Ciuleanu T., Dediu M., Ganea-Motan E., Lubenau H., Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009, 4(6):736-740.
33. Congressional Budget Office Cost estimate: S. 1695 Biologics Price Competition and Innovation Act of 2007 Available at:, [Accessed on July 1st, 2014]. http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/94xx/doc9496/s1695.pdf.
34. Generics and Biosimilars Initiative Definitions of biosimilars Available at, [Accessed on August 1st, 2014]. http://gabionline.net/Biosimilars/General/WHO-definitions-of-biosimilars.
35. Gascon P., Fuhr U., Sörgel F., Kinzig-Schippers M., Makhson A., Balser S., et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010, 21(7):1419-1429.
36. Waller C.F., Bronchud M., Mair S., Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010, 89(10):971-978.
37. Waller C.F., Bronchud M., Mair S., Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010, 89(9):927-933.
38. Waller C.F., Semiglazov V.F., Tjulandin S., Bentsion D., Chan S., Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010, 33(10):504-511.